Consequently, there are targeted therapies available that are directed at variants in the EGFR gene in newly diagnosed patients with non-squamous advanced NSCLC that have been approved by the US Food and Drug Administration (FDA) [12, 14] and, from 2018, testing of this gene has been considered a minimum requirement per guidelines from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology [14]. Here, EGFR is linked to lung carcinoma.